UK biotech round-up: Autolus joins CAR-T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit – pharmaphorum
|
UK biotech round-up: Autolus joins CAR–T race, Horizon's new CRISPR tech, Allergy Therapeutics' grass gambit
pharmaphorum “BCMA CAR–T cell therapies have shown considerable promise in early clinical studies. A dual-targeted approach may minimise the risk for antigen negative escape and extend CAR-T treatment to patients with low density of BCMA antigen on the surface … Syncona's Autolus begins three T-cell cancer trials | Digitallook.com Arix Bioscience plc notes positive clinical study announcements from Autolus Limited Arix Bioscience Notes Autolus Ltd's Updates On Clinical Progress … |
